CAD is a rare, chronic, autoimmune haemolytic anaemia that shouldn’t be confused with cold agglutinin syndrome (CAS) secondary to infection or cancer1,4
In CAD, activated C1 triggers the classical complement pathway and drives chronic haemolysis4
Patients can face risks for severe anaemia and possible life-threatening TEs despite current management3,5
Profound fatigue and life-limiting burden persist despite current management6-10
There are specific criteria to diagnose CAD
See the goals for future CAD treatment
Sanofi is committed to ongoing CAD research.
CAD=Cold Agglutinin Disease; CAS=cold agglutinin syndrome; TE=thromboembolic event.
References: 1. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12(5):361-370. doi:10.1080/10245330701445392 2. Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839-848. doi:10.1182/bloodadvances.2017004390 3. Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4(4):628-635. doi:10.1002/rth2.12333 4. Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55(3):141-149. doi:10.1053/j.seminhematol.2018.04.002 5. Kamesaki T, Nishimura J-i, Wada H, et al. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol. 2020:112(3):307-315. doi:10.1007/s12185-020-02899-6 6. Su J, Kosa K, DiBenedetti D. Patient-reported disease burden: in-depth interviews of patients with CAD. Blood. 2020;136(suppl 1):29-30. doi:10.1182/blood-2020-136788
7. Patel P, Jiang X, Nicholson G et al. Medically attended anxiety or depression is increased among newly diagnosed patients with cold agglutinin disease (CAD). Blood. 2020;136(suppl 1):28. doi.org/10.1182/blood-2020-139791 8. Vágó EK, Nicholson G, Horváth-Puhó E, Hooda N, Fryzek JP, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin. 2021;37(10):1829-1835. doi: 10.1080/03007995.2021.1960494 9. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121. doi:10.1182/blood-2013-02-474437 10. Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev. 2012;26(3):107-115. doi:10.1016/j.blre.2012.01.002
MAT-GLB-2201058-v1.0-05/2022